Navigation Links
FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
Date:5/13/2008

First Recombinant Room Temperature Stable Treatment for Hemophilia With

Inhibitors Offers More Flexibility and Convenience to Patients

PRINCETON, N.J., May 13 /PRNewswire-FirstCall/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable), the first room temperature stable recombinant product available for the treatment of bleeding episodes in patients with hemophilia with inhibitors. NovoSeven(R) RT is a new formulation of NovoSeven(R) (Coagulation Factor VIIa [Recombinant]) designed to provide patients with added flexibility when treating their condition.

Hemophilia is a chronic, inherited bleeding disorder that primarily affects males. It is a sex-linked condition, meaning that it is passed on from mother to child on the X chromosome. Approximately 18,000 people in the United States have hemophilia. Thirty percent of these people can develop a complication known as inhibitors. The development of inhibitors is a complication whereby antibodies to conventional factor replacement treatment develop, making treatment more difficult.

"People with hemophilia, who already make lifestyle compromises because of this disorder, are often encumbered by their treatments. As a result, going places or participating in any activity outside the home becomes more difficult because treatment portability, preparation, and administration have been restrictive," stated Eddie Williams, Vice President, Biopharmaceuticals, at Novo Nordisk. "Novo Nordisk is constantly looking for ways to help solve the unique challenges these patients face. The new NovoSeven(R) RT provides the same safety and efficacy as the original NovoSeven(R)-but it can be transported and administered quickly."

NovoSeven(R) RT has been manufactured to be room temperature stable (from 36 degrees F to 77 degrees F outside a refrigerator). The new formulation does not
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
2. FDA Approves Health Claim for Brown Rice
3. FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents
4. FDA approves HeartMate II mechanical heart pump for heart-failure patients
5. FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
6. FDA Approves New Once-a-Month Dose of Actonel for Postmenopausal Osteoporosis
7. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
8. FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE
9. House Overwhelmingly Approves Renewal and Tripling of Successful U.S. Global AIDS Prevention Effort
10. VeriPrime Approves New Best Practices for Beef Production
11. U.S. EPA Approves Registration of Antimicrobial Copper Alloys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 2014 A new sports massage ... pain-relief service and massage therapy provider, announced it ... This newest sports massage is a ... between traditional sports massage and ESM is that ... very own "reset button,” and ESM can increase ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 The Holiday ... the Family and Children's Association to donate ... soap, shampoo, mouthwash and other such items.The Association's program ... are home bound, living in nursing homes, assisted living ... greatly enhance the well being of seniors throughout the ...
(Date:11/24/2014)... The typical American diet includes foods ... Consistently consuming a diet high in calories and carbohydrates ... fat that typically accumulate around the internal organs exposing ... head in the form of love handles, beer bellies ... decision to rid themselves of the burden of embarrassing, ...
(Date:11/24/2014)... York (PRWEB) November 24, 2014 Gersowitz Libo ... that it has received national Tier recognition in the 2015 ... Achieving a tiered ranking signals a unique combination of quality ... very proud to receive this honor and especially grateful to ... this important honor and ranking possible,” said Jeff S. Korek, ...
(Date:11/23/2014)... 2014 The clinical trial report, ... data on the Aspergillosis clinical trial scenario. This ... the clinical trials on Aspergillosis. It includes an ... status as per the site of trial conduction ... coverage of disease clinical trials by their phase, ...
Breaking Medicine News(10 mins):Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 2Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 3Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 4Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4
... A study of kidney dialysis patients found that nearly ... that is a predictor of cardiovascular disease// , at ... illuminates the relationship between heart and kidney disease, as ... risk of cardiovascular problems. ,“Metabolic syndrome is ...
... were housed under asbestos roofs. The children of the sixties, ... living their childhood days under asbestos roofs, known to be ... 5% of all lung cancers in the United Kingdom happen ... medical term used to describe a cancer in the lining ...
... St. Jude Children’s Research Hospital have discovered previously unsuspected ... lymphoblastic leukemia (ALL), // the most common cancer in ... treating pediatric ALL, but also provides a roadmap for ... ,ALL is a tumor in which immature ...
... pizza or spaghetti, make sure it’s made from orange tomatoes, not ... State University have reported findings, which state that lycopene- the well-known ... it comes from tomatoes that are orange in color. ... and Food Chemistry. ,Lycopene is said to ...
... study on sleep patterns in American women found that most of ... and physical health// , personal lives, professional work and driving safety. ... Foundation, studied about 1,003 adult women in ages 18 t0 65 ... get less than one or two nights of good sleep each ...
... on the Atkins low-carbohydrate diet lose more weight than those ... pressure and cholesterol levels dropped considerably. ,On average, ... months. The average weight loss was 5.7 pounds for women ... diet and 3.5 pounds for those following the Zone weight-loss ...
Cached Medicine News:Health News:Major Gene Study Uncovers Secrets of Leukemia 2Health News:Major Gene Study Uncovers Secrets of Leukemia 3Health News:Pass the Orange Tomato Sauce Please 2Health News:Sleep Problems of Women 2Health News:Atkin’s Low-carb Diet Best for Weight Los 2
(Date:11/24/2014)...  Pifflers United Chronic and Invisible Illnesses Support ... results of a study of ActiPatch®, a new ... fibromyalgia pain. The results demonstrated that when used ... clinically meaningful pain reduction can be achieved. ... used ActiPatch® for 7 days and were then ...
(Date:11/23/2014)... 23, 2014  Aurobindo Pharma USA ... USP 300 mg 100-count bottles to the consumer level. ... empty capsules. Empty capsules could result in ... that could range from no effect, short term reduction ... (long period seizures) that could be life-threatening. Aurobindo Pharma ...
(Date:11/22/2014)... N.J. , Nov. 21, 2014  CytoSorbents ... commercializing its European Union approved CytoSorb® cytokine adsorber ... was awarded the Beacon of Light Award at ... Celebration.  Dr. Phillip Chan ... is an honor to be recognized by the ...
Breaking Medicine Technology:Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
... , The Danish Statens Serum Institut (SSI) and Intercell, ... I clinical,trial with a tuberculosis (TB) subunit vaccine , , » ... contains Intercell’s,adjuvant IC31™ , , » ... , replace the available TB,vaccine “BCG”/“Calmette vaccine” ...
... that its,collaboration partner AtheroGenics, Inc. (Nasdaq: AGIX) ... of Inflammation,Stops Events) phase III clinical outcomes ... with,antioxidant and anti-inflammatory effects, in patients with,coronary ... not meet its primary endpoint of a,statistically ...
Cached Medicine Technology:Intercell AG: Novel tuberculosis Vaccine Shows Promising,Immunogenicity and Safety Profile 2Intercell AG: Novel tuberculosis Vaccine Shows Promising,Immunogenicity and Safety Profile 3Intercell AG: Novel tuberculosis Vaccine Shows Promising,Immunogenicity and Safety Profile 4Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet,Primary Endpoint 2
... Ultra has an uniquely designed ... facility in which tubes are ... the same carrying tray. Spin ... magnifier, quiet operation, automatic electric ...
... The Rotanta 460 family ... extraordinary line that meets ... demands. They feature high ... Their state-of-the-art technology and ...
... Coolscope operates with a simple click ... display. Direct the mouse cursor to ... image of the slide and the ... intuitive Graphic User Interface (GUI) enables ...
Continuous rocking motion graphic display....
Medicine Products: